MOLECULES-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2022-08-22 361152897

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：单体;动物疾病模型
经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。

127 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2022-11-07 含

WB需要全膜带Marker的原始数据吗

122 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2024-11-21 xixi@haha 来自山东省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤
经验分享：相对较易

32 0

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2024-08-11 ms9000001549086549 来自山东省

无

60 0

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2024-08-11 ms9000001549086549 来自山东省

🈚️，

158 0

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2019-03-20 ms493637184140865

审稿速度:1.0
经验分享：存在投稿就被要求提供作者签字的情况

222 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2023-07-26 ms9000001976206462 来自广东省

四天前发了邮件给编辑部，到现在都没回，我太难了

122 0

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2022-08-22 1e0c52fcm39(暂无匿称)

审稿速度:1.0 | 投稿命中率:75.0
经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。

150 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2023-03-05 ms1000001854041919 来自北京

伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？

124 0

[GetPortalCommentsPageByObjectIdResponse(id=1240378, encodeId=c9df12403e837, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单体;动物疾病模型 经验分享：两个审稿人均要求疯狂补实验，要求很苛刻，大修两次，终于接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=01c92285047, createdName=361152897, createdTime=Mon Aug 22 22:27:34 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098959, encodeId=afd520989595f, content=WB需要全膜带Marker的原始数据吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2f0d2095817, createdName=含, createdTime=Mon Nov 07 13:16:41 CST 2022, time=2022-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2238161, encodeId=d6e72238161c2, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤 经验分享：相对较易, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/F5C63C7923C3AA7257DA34E941F6C689/100, createdBy=0a4f2031706, createdName=xixi@haha, createdTime=Thu Nov 21 13:55:32 CST 2024, time=2024-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219571, encodeId=9b1d22195e178, content=无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 15:42:01 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2219575, encodeId=838f22195e5d6, content=🈚️，, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58c79419150, createdName=ms9000001549086549, createdTime=Sun Aug 11 16:01:25 CST 2024, time=2024-08-11, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=850360, encodeId=17db85036081, content=审稿速度:1.0 经验分享：存在投稿就被要求提供作者签字的情况 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=baad5414143, createdName=ms493637184140865, createdTime=Wed Mar 20 10:47:17 CST 2019, time=2019-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149996, encodeId=00be2149996b3, content=四天前发了邮件给编辑部，到现在都没回，我太难了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb368660953, createdName=ms9000001976206462, createdTime=Wed Jul 26 20:27:40 CST 2023, time=2023-07-26, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1240251, encodeId=192c12402515c, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下经验，之前接受到杂志的约稿邮件，然后整理数据将文章投上去，投的是杂志特刊，做的是药物治疗疾病的研究和机制探讨，特别要表扬的是编辑，超级超级超级。。。Nice，真的是有问必回，而且特别高效。送了3个审稿人，然后经历过一次小修（5天时间要求修回），收到接收函的第二天proof和invoice就来了，proof要求24小时内提交，付款要求5天内完成。从投到接收不到1个月。因为是约稿，版面费还有优惠，所以该杂志值得投稿，良心杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=150, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8c811928827, createdName=1e0c52fcm39(暂无匿称), createdTime=Mon Aug 22 11:15:01 CST 2022, time=2022-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2117818, encodeId=e1e5211e818bf, content=伦理要求上传Patient Consent Form for Articles Containing Patient Details and/or Images。能否使用representative，Relationship of representative to patient这一部分怎么填啊？ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7475559954, createdName=ms1000001854041919, createdTime=Sun Mar 05 23:07:34 CST 2023, time=2023-03-05, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=915861, encodeId=048e9158618d, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/03/a49c0c976fe7f81b1448833c8538aa24.jpg, createdBy=cb9a1630518, createdName=Rtase, createdTime=Tue Jan 12 11:40:34 CST 2021, time=2021-01-12, status=1, ipAttribution=)]

2021-01-12 Rtase

审稿速度:1.0 | 投稿命中率:50.0
经验分享：这杂志一审居然4个审稿人，3小修一拒，给了个大修！

311 10

展开10条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务